Press Releases Year All News | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | Sep 28, 2022 gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma Sep 27, 2022 TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors Sep 26, 2022 TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit Sep 01, 2022 TCR2 Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 08, 2022 TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Aug 01, 2022 TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 01, 2022 TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 27, 2022 TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer Jun 01, 2022 TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 01, 2022 TCR² Therapeutics to Participate in Two Upcoming Conferences in June Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »